Ryan Newton, BSC/MBA

Vaccine Research and Development, Pfizer Ltd
Marlow, England, United Kingdom

Disclosure(s): Pfizer Inc: Employee, Stocks/Bonds (Private Company)

Presentation(s):

• 571 - Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

  Saturday, October 19, 2024
  1:45 PM – 2:03 PM US PT